Detalles de la búsqueda
1.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Ann Oncol
; 33(11): 1168-1178, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973665
2.
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Ann Oncol
; 31(8): 1056-1064, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32418886
3.
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
ESMO Open
; 7(6): 100612, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36375271
4.
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
ESMO Open
; 7(1): 100333, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042152
Resultados
1 -
4
de 4
1
Próxima >
>>